Pharmacogenomics of anticancer drugs: Personalising the choice and dose to manage drug response
Open Access
- 30 June 2020
- journal article
- review article
- Published by Wiley in British Journal of Clinical Pharmacology
- Vol. 87 (2) , 237-255
Abstract
The field of pharmacogenomics has made great strides in oncology over the last 20 years and indeed a significant number of pre‐emptive genetic tests are now routinely undertaken prior to anticancer drug administration. Many of these gene–drug interactions are the fruits of candidate gene and genome‐wide association studies, which have largely focused on common genetic variants (allele frequency>1%). Examples where there is clinical utility include genotyping or phenotyping for G6PD to prevent rasburicase‐induced RBC haemolysis, and TPMT to prevent thiopurine‐induced bone marrow suppression. Other associations such as CYP2D6 status in determining the efficacy of tamoxifen are more controversial because of contradictory evidence from different sources, which has led to variability in the implementation of testing.As genomic technology becomes ever cheaper and more accessible, we must look to the additional data our genome can provide to explain interindividual variability in anticancer drug response. Clearly genes do not act on their own and it is therefore important to investigate genetic factors in conjunction with clinical factors, interacting concomitant drug therapies and other factors such as the microbiome, which can all affect drug disposition. Taking account of all of these factors, in conjunction with the somatic genome, is more likely to provide better predictive accuracy in determining anticancer drug response, both efficacy and safety.This review summarises the existing knowledge related to the pharmacogenomics of anticancer drugs and discusses areas of opportunity for further advances in personalisation of therapy in order to improve both drug safety and efficacy.Keywords
This publication has 157 references indexed in Scilit:
- The Electronic Medical Records and Genomics (eMERGE) Network: past, present, and futureGenetics in Medicine, 2013
- Reduced CYP2D6 function is associated with gefitinib-induced rash in patients with non-small cell lung cancerBMC Cancer, 2012
- Rare versus common variants in pharmacogenetics: SLCO1B1 variation and methotrexate dispositionGenome Research, 2011
- Very important pharmacogene summaryPharmacogenetics and Genomics, 2011
- HLA-DQA1*02:01 Is a Major Risk Factor for Lapatinib-Induced Hepatotoxicity in Women With Advanced Breast CancerJournal of Clinical Oncology, 2011
- Alleviating Cancer Drug Toxicity by Inhibiting a Bacterial EnzymeScience, 2010
- Pazopanib-induced hyperbilirubinemia is associated with Gilbert's syndrome UGT1A1 polymorphismBritish Journal of Cancer, 2010
- Review: Chemotherapy-induced diarrhea: pathophysiology, frequency and guideline-based managementTherapeutic Advances in Medical Oncology, 2009
- Hypermethylation of the DPYD promoter region is not a major predictor of severe toxicity in 5-fluorouracil based chemotherapyJournal of Experimental & Clinical Cancer Research, 2008
- Association of ABCB1 genotypes with paclitaxel-mediated peripheral neuropathy and neutropeniaEuropean Journal of Cancer, 2006